CAM2029 (octreotide subcutaneous depot) for Acromegaly

Phase-Based Progress Estimates
Hospital Clinic Barcelona, Barcelona, SpainAcromegalyCAM2029 (octreotide subcutaneous depot) - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing the long-term safety of a drug called CAM2029 in patients with a condition called acromegaly. Patients will get the drug once a month for 12 months, and then may be able to keep getting it for another year.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Week 50 to 52

Week 0-52
Characterization of adverse events (AEs)
Octreotide plasma concentrations over time
Proportion of patients/partners declared competent by a healthcare professional to administer intervention
Week 50 to 52
Proportion of patients with mean GH levels <2.5 µg/L and <5.0 µg/L
Proportion of patients with mean IGF-1 levels ≤1xULN and ≤1.3xULN

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

CAM2029 (octreotide subcutaneous depot)
1 of 1

Experimental Treatment

140 Total Participants · 1 Treatment Group

Primary Treatment: CAM2029 (octreotide subcutaneous depot) · No Placebo Group · Phase 3

CAM2029 (octreotide subcutaneous depot)
Experimental Group · 1 Intervention: CAM2029 (octreotide subcutaneous depot) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 50 to 52

Who is running the clinical trial?

Camurus ABLead Sponsor
8 Previous Clinical Trials
1,693 Total Patients Enrolled
2 Trials studying Acromegaly
84 Patients Enrolled for Acromegaly
Diego Ferone, M.DPrincipal InvestigatorUniversity of Genova Endocrinology Unit

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a medical history of acromegaly that is still present or keeps coming back.
You have been taking octreotide LAR or lanreotide ATG consistently for three months before being screened.

Frequently Asked Questions

Are there any other ongoing or completed research studies that have used CAM2029 (octreotide subcutaneous depot)?

"CAM2029 (octreotide subcutaneous depot) was first studied in 1997 at Vanderbilt University Autonomic Dysfunction Center. Since the initial study, 105 more have been completed with 16 presently active and recruiting patients. The majority of these studies are based out of Missouri's largest city, Saint Louis." - Anonymous Online Contributor

Unverified Answer

For what purpose is CAM2029 (octreotide subcutaneous depot) most often prescribed?

"octreotide is frequently treated with CAM2029 (octreotide subcutaneous depot). Other conditions that this medication can help manage include long-term maintenance therapy, acromegaly, and metastatic carcinoid tumors." - Anonymous Online Contributor

Unverified Answer

At how many different test sites is this research being conducted?

"There are 11 sites enrolling patients for this clinical trial, which include locations such as Saint Louis, Los Angeles and Cincinnati. To reduce the burden of travel on participants, it is best to select a location closest to you." - Anonymous Online Contributor

Unverified Answer

Has CAM2029 (octreotide subcutaneous depot) received FDA approval?

"CAM2029 (octreotide subcutaneous depot) has been given a safety rating of 3. This is based on the fact that it is currently in Phase 3 clinical trials, meaning that there is both evidence of efficacy and multiple rounds data supporting its safety." - Anonymous Online Contributor

Unverified Answer

Does this experiment still need more test subjects?

"This information can be found on; the study is still recruiting patients and was first posted on 10/10/2019 with a most recent edit on 9/1/2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.